Clinical trials: Clopidogrel
Diabetes Mellitus, Type 2, NSTEMI - Non-ST Segment Elevation MI
Incidence of Major Cardiovascular Events in Diabetic Patients With ACS Undergoing Coronary Angioplasty and Treated With Clopidogrel 150 mg Versus 75 mg
Acute Coronary Syndrome (ACS) is triggered by the rupture of an atherosclerotic plaque that results in a platelet aggregation reaction in the coronary artery.
- Conditions
- Diabetes Mellitus, Type 2, NSTEMI - Non-ST Segment Elevation MI, Coronary Angioplasty
- Trial name
- IDASCOP 1 (NCT03329261)
- Testing
- Clopidogrel
- Where
- Tunisia
- Volunteers
- 167 people
- Sponsor
- Laboratoires Teriak
Coronary Artery Disease
A Study of the Onset and Offset of Antiplatelet Effects Comparing Ticagrelor, Clopidogrel, and Placebo With Aspirin
The purpose of this study is to see how Ticagrelor, a new oral reversible anti-platelet medication, affects platelets. Anti-platelet agents are medications that block the formation of blood clots by preventing the clumping of…
- Trial name
- NCT00528411
- Testing
- Ticagrelor Tablets, Clopidogrel (over encapsulated) capsule, Aspirin Tablets
- Where
- 9 sites in United States, United Kingdom
- Volunteers
- 123 people
- Sponsor
- AstraZeneca
Healthy
Interaction Study of Clopidogrel 300/75 mg Given Alone or With Omeprazole 80 mg 12 Hours Apart in Healthy Subjects
Primary objective: Assess the effects of clopidogrel (300 mg loading dose followed by 4 days 75 mg/day) on Adenosine diphosphate (ADP)-induced platelet aggregation when given either alone in the morning, or in association with…
- Trial name
- NCT01129388
- Testing
- clopidogrel, omeprazole
- Where
- United States
- Volunteers
- 72 people, healthy volunteers welcome
- Sponsor
- Sanofi
Healthy
Food Study of Clopidogrel Bisulfate Tablets 75 mg to Plavix® Tablets 75 mg
The objective of this study was to investigate the bioequivalence of Mylan's clopidogrel bisulfate 75 mg tablets to Bristol-Myers Squibb/Sanofi's Plavix® 75 mg tablets following a single, oral 75 mg (1 x 75 mg) dose administered…
- Trial name
- NCT00650169
- Testing
- Clopidogrel Bisulfate Tablets 75 mg, Plavix® Tablets 75 mg
- Where
- United States
- Volunteers
- 47 people, healthy volunteers welcome
- Sponsor
- Mylan Pharmaceuticals Inc
Healthy
Influence of Clopidogrel on the Pharmacodynamics and Safety of Fradafiban in Healthy Male Subjects
To assess the influence of 75 mg Clopidogrel on the pharmacodynamics and safety of 30 mg Lefradafiban tid
- Trial name
- NCT02265289
- Testing
- Lefradafiban, Clopidogrel
- Volunteers
- 14 people, healthy volunteers welcome
- Sponsor
- Boehringer Ingelheim
Coronary Artery Disease
Phase IV Study to Compare Efficacy and Safety of Plavix 75mg With Astrix 100mg and Closone
The Aim of this study is to prove non-inferiority of Closone to the Combination treatment of Plavix with Astrix.
- Trial name
- NCT01765452
- Testing
- Closone, Plavix with Astrix
- Where
- 7 sites in South Korea
- Volunteers
- 285 people
- Sponsor
- HK inno.N Corporation
Healthy
Effect of Tegoprazan on Pharmacodynamics of Clopidogrel in Healthy Male Participants
This study aims to evaluate the influence of tegoprazan on the pharmacodynamics of clopidogrel according to CYP2C19 genotypes following co-administration of tegoprazan and clopidogrel in healthy male volunteers.
- Trial name
- NCT03814642
- Testing
- Clopidogrel 75 mg, Tegoprazan 50 mg, Esomeprazole 20 mg
- Where
- South Korea
- Volunteers
- 25 people, healthy volunteers welcome
- Sponsor
- HK inno.N Corporation
Healthy
Influence of Rabeprazole on the Magnitude of the Antiplatelet Action of Clopidogrel
The purpose of this study is to assess, whether the administration of a proton pump inhibitor, Rabeprazole, has a negative effect on the activity of a concomitantly administered blood thinner drug.
- Trial name
- CLARA (NCT00989300)
- Testing
- Treatment A - rabeprazole, Treatment B - omeprazole
- Volunteers
- 39 people, healthy volunteers welcome
- Sponsor
- Janssen Cilag S.A.S.
Atrial Fibrillation, Percutaneous Coronary Intervention
Evaluation of Dual Therapy With Dabigatran vs. Triple Therapy With Warfarin in Patients With AF That Undergo a PCI With Stenting (REDUAL-PCI)
The main objective of this study is to compare a Dual Antithrombotic Therapy (DAT) regimen of 110mg dabigatran etexilate b.i.d. plus clopidogrel or ticagrelor (110mg dabigatran etexilate (DE) DAT) and 150mg dabigatran etexilate…
- Trial name
- NCT02164864
- Testing
- Dabigatran Etexilate 110mg, Warfarin 3mg, Aspirin
- Where
- 421 sites in United States, Argentina and 39 more
- Volunteers
- 2,725 people
- Sponsor
- Boehringer Ingelheim
Peripheral Arterial Disease
Effect of Plavix on NO (Nitrogen Monoxide) Production of the Endothelial Function
To determine whether in the laser Doppler flowmetric parameters characteristic of endothelial dysfunction at patients with clinically manifest atherosclerosis any change can be detected at plavix (clopidogrel) treatment.
- Trial name
- NCT00648453
- Testing
- Clopidogrel (Plavix)
- Where
- Hungary
- Volunteers
- 39 people
- Sponsor
- Sanofi
Acute Coronary Syndrome, Percutaneous Coronary Intervention
Study to Assess Safety and Efficacy of Ticagrelor (AZD6140) Versus Clopidogrel in Asian/Japanese Patients With Non-ST or ST Elevation Acute Coronary Syndromes (ACS)
The purpose of the study is to assess the efficacy (prevention of vascular events) and safety (especially bleedings) of Ticagrelor (AZD6140) compared with Clopidogrel, both given on top of low dose aspirin, in Asian/Japanese…
- Trial name
- NCT01294462
- Testing
- Ticagrelor, Clopidogrel, Acetylsalicylic acid ASA
- Where
- 87 sites in Japan, South Korea and 1 more
- Volunteers
- 801 people
- Sponsor
- AstraZeneca
Coronary Disease
Clinical Assessment of Pidogrel® Versus Plavix® (CAPP)
This study aims to demonstrate non-inferiority of Pidogrel ® compared to Plavix ® in patients with coronary disease: Primary Outcome Measures: measure of platelet reactivity by VerifyNow assay after 600 mg loading dose or after…
- Trial name
- (CAPP) (NCT01431495)
- Testing
- Pidogrel, Plavix
- Where
- Tunisia
- Volunteers
- 219 people
- Sponsor
- Les Laboratoires des Médicaments Stériles
Coronary Artery Disease
Comparison of Prasugrel and Clopidogrel in Low Body Weight Versus Higher Body Weight With Coronary Artery Disease
The 5-milligram (mg) dose of prasugrel in low body weight (LBW) patients with coronary artery disease produces a pharmacodynamic response within the same therapeutic range as 10-mg dose in higher body weight (HBW) patients.
- Trial name
- FEATHER (NCT01107925)
- Testing
- prasugrel, clopidogrel
- Where
- 6 sites in United States, Ireland and 2 more
- Volunteers
- 72 people
- Sponsor
- Eli Lilly and Company
Acute Coronary Syndrome
Dose-escalation, Repeated and Single Oral Dosing Study
Randomized, Double-blind, Placebo-controlled, Dose-escalation, Repeated and Single Oral Dosing Phase I Study to Assess the Pharmacokinetics, Pharmacodynamics and Safety of APD791 (Temanogrel) Co-administered with Aspirin and…
- Trial name
- NCT02419820
- Testing
- APD791, Clopidogrel, Aspirin
- Volunteers
- 104 people, healthy volunteers welcome
- Sponsor
- IlDong Pharmaceutical Co Ltd
Pharmacodynamic Interaction, Healthy Subjects
To Evaluate Whether Acetyl Salicylic Acid (Aspirin), the Combination of Aspirin and Clopidogrel and Darexaban (YM150) Interact in Their Effects
The primary objective of this study is to evaluate whether ASA, the combination of ASA and clopidogrel, and darexaban, which have different effects on blood coagulation, influence each other in their effects.
- Trial name
- NCT01409616
- Testing
- darexaban, darexaban (double dose), Acetyl Salicylic Acid
- Where
- France
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- Astellas Pharma Inc
Fasting
Bioequivalence Study of Clopidogrel Tablets 300 mg Under Fasting Conditions
To compare the bioavailability and characterize the pharmacokinetic profile of the Sponsor's formulation (Clopidogrel Bisulfate 300 mg Tablets) with respect to the reference formulation (Plavix® 300 mg tablets) in healthy, adult…
- Trial name
- NCT01621750
- Testing
- Clopidogrel
- Where
- India
- Volunteers
- 68 people, healthy volunteers welcome
- Sponsor
- Dr. Reddy's Laboratories Limited
Atrial Fibrillation, Percutaneous Coronary Intervention
A Study Exploring Two Strategies of Rivaroxaban (JNJ39039039; BAY-59-7939) and One of Oral Vitamin K Antagonist in Patients With Atrial Fibrillation Who Undergo Percutaneous Coronary Intervention
The primary purpose of this study is to evaluate the safety for 2 different rivaroxaban treatment strategies and one Vitamin K Antagonist (VKA) treatment strategy utilizing various combinations of dual antiplatelet therapy (DAPT)…
- Trial name
- PIONEER AF-PCI (NCT01830543)
- Testing
- rivaroxaban 2.5 mg, rivaroxaban 15 mg, rivaroxaban 10 mg
- Where
- 348 sites in United States, Argentina and 23 more
- Volunteers
- 2,124 people
- Sponsor
- Janssen Scientific Affairs, LLC
Cerebral Infarction
Safety and Efficacy of Clopidogrel for Cerebral Infarction Treatment
The primary objective is to compare the safety of clopidogrel 50mg and 75mg in cerebral infarction with respect to incidence of bleeding adverse events.
- Trial name
- NCT00386191
- Testing
- clopidogrel (SR25990C)
- Where
- Japan
- Volunteers
- 1,110 people
- Sponsor
- Sanofi
Healthy
Pharmacokinetics/Pharmacodynamics (PK/PD) of Cangrelor
The purposes of this study are to: Evaluate the tolerability of two cangrelor regimens. Compare the PD of cangrelor regimens with oral clopidogrel.
- Trial name
- NCT00102674
- Testing
- cangrelor
- Where
- United States
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- The Medicines Company
Acute Coronary Syndrome
Comparative Pharmacokinetics of YH14659
The objective of this study is to compare pharmacokinetics after single oral administration of 2 capsules of YH14659, a fixed-dose combination of clopidogrel and aspirin developed by Yuhan Corporation versus co-administration of…
- Trial name
- YH14659 (NCT01422109)
- Testing
- YH14659, clopidogrel & aspirin
- Where
- South Korea
- Volunteers
- 44 people, healthy volunteers welcome
- Sponsor
- Yuhan Corporation